QURE

QURE

USD

uniQure N.V. Ordinary Shares

$30.440-0.370 (-1.201%)

即時價格

Healthcare
生物科技
荷蘭

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$30.810

最高

$32.490

最低

$28.500

交易量

8.90M

公司基本面

市值

1.9B

行業

生物科技

國家

Netherlands

交易統計

平均交易量

3.75M

交易所

NMS

貨幣

USD

52週範圍

最低 $5.35當前 $30.440最高 $71.5

相關新聞

GlobeNewswire

uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (QURE)

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE). The investigation concerns whether the

查看更多
Analyst Upgrades

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

查看更多
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Analyst Upgrades

Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38

Goldman Sachs analyst Salveen Richter maintains uniQure with a Neutral and lowers the price target from $56 to $38.

查看更多
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38
Analyst Upgrades

RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45

RBC Capital analyst Luca Issi maintains uniQure with a Outperform and lowers the price target from $65 to $45.

查看更多
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45
Analyst Upgrades

William Blair Downgrades uniQure to Market Perform

William Blair analyst Sami Corwin downgrades uniQure from Outperform to Market Perform.

查看更多
William Blair Downgrades uniQure to Market Perform
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure with a Buy and lowers the price target from $110 to $70.

Analyst Upgrades

Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $53

Chardan Capital analyst Daniil Gataulin maintains uniQure with a Buy and lowers the price target from $76 to $53.